- €86.19bn
- €103.69bn
- €46.72bn
Top Weil dealmaker to depart with M&A team for rival law firm Cravath
Focus: Novartis investors turn spotlight on M&A after trial setbacks
Europe Research Roundup: AstraZeneca, GSK, Kingspan Group
To re-rate, Sanofi needs to show tangible progress - RBC starts at 'sector perform'
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Corrected: UPDATE 2-Novartis MS pill beats older drug in trials, boosts pipeline hopes
Brief: Sanofi Spokesperson Says Nuvaxovid to Be Available Across U.S. for 2026-27 Respiratory Virus Season
US FDA approves updated COVID vaccines for 2026-27 season
Brief: EMA Says Sanofi Winthrop Industrie Withdrew Its Application For Use Of Dupixent On June 24
Factbox: Global drugmakers invest billions to boost US presence
Factbox: Global drugmakers invest billions to boost US presence
Novavax raises annual revenue forecast as licensing bets offset weak vaccine demand (updated)
Novavax lifts annual revenue forecast as licensing bets offset weak vaccine demand
US FDA approves first mRNA flu shot from Moderna
Brief: EU Approves Sanofi's Menquadfi To Treat Infants Against Invasive Meningococcal Disease
Brief: Sanofi Expects Moderate Increases In R&D Spend
Regeneron beats quarterly estimates on eczema drug strength, shares rise
Sanofi drug pipeline worries, Dupixent dependence shake shares (updated)